{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:07:06Z","timestamp":1793300826071,"version":"4.5.0"},"reference-count":104,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Breast cancer faces significant therapeutic challenges, particularly for triple-negative breast cancer (TNBC), due to limited targeted therapies and drug resistance. Drug repositioning leverages existing safety and pharmacokinetic data to expedite the identification of new indications with cost-effective benefits compared to de novo drug discovery. In this critical narrative review, we examine recent advances in computational repositioning strategies for breast cancer, focusing on network-based methods, computer-aided drug design, artificial intelligence and machine learning, transcriptomic signature matching, and multi-omics integration. We highlight key case studies that have progressed to preclinical validation or clinical evaluation. We assess comparative performance metrics, experimental validation outcomes, and real-world success rates. We also present critical methodological challenges, including data heterogeneity, bias in real-world data, and the need for study reproducibility. Our review emphasizes the importance of window-of-opportunity trials and the need for standardized data sharing and reproducible pipelines. These insights highlight the groundbreaking potential of in silico repositioning in addressing unmet needs in breast cancer therapy.<\/jats:p>","DOI":"10.3390\/medicina61091640","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:04:55Z","timestamp":1757505895000},"page":"1640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Redefining Breast Cancer Care by Harnessing Computational Drug Repositioning"],"prefix":"10.3390","volume":"61","author":[{"given":"Elena-Daniela","family":"Jurj","sequence":"first","affiliation":[{"name":"Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2449-3452","authenticated-orcid":false,"given":"Daiana","family":"Colib\u0103\u0219anu","sequence":"additional","affiliation":[{"name":"Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Departament II\u2014Pharmaceutical Chemistry, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1156-8825","authenticated-orcid":false,"given":"Sabina-Oana","family":"Vasii","sequence":"additional","affiliation":[{"name":"Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-3275","authenticated-orcid":false,"given":"Liana","family":"Suciu","sequence":"additional","affiliation":[{"name":"Department II\u2014Pharmacology-Pharmacotherapy, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u015foara, 300041 Timi\u015foara, Romania"},{"name":"Research Center for Pharmaco-Toxicological Evaluations, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u015foara, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Adriana","family":"Dehelean","sequence":"additional","affiliation":[{"name":"Research Center for Pharmaco-Toxicological Evaluations, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u015foara, 300041 Timi\u015foara, Romania"},{"name":"Departament I\u2014Toxicololgy, Drug Industry, Management and Legislation, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-6301","authenticated-orcid":false,"given":"Lucre\u021bia","family":"Udrescu","sequence":"additional","affiliation":[{"name":"Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Departament I\u2014Drug Analysis, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"WHO (2025, April 30). Breast Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., and Cho, W.C. (2019). Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed. Pharmacother., 114.","DOI":"10.1016\/j.biopha.2019.108800"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gote, V., Nookala, A.R., Bolla, P.K., and Pal, D. (2021). Drug resistance in metastatic breast cancer: Tumor targeted nanomedicine to the rescue. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094673"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","first-page":"1233","article-title":"Understanding and treating triple-negative breast cancer","volume":"22","author":"Anders","year":"2008","journal-title":"Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Peerschke, E.I., Stanchina, E.d., Chang, Q., Manova-Todorova, K., Barlas, A., Savitt, A.G., Geisbrecht, B.V., and Ghebrehiwet, B. (2020). Anti gC1qR\/p32\/HABP1 antibody therapy decreases tumor growth in an orthotopic murine xenotransplant model of triple negative breast cancer. Antibodies, 9.","DOI":"10.3390\/antib9040051"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10549-017-4383-5","article-title":"Risk of mortality of node-negative, ER\/PR\/HER2 breast cancer subtypes in T1, T2, and T3 tumors","volume":"165","author":"Parise","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_13","unstructured":"(2025, May 25). Deloitte.com. Measuring the Return from Pharmaceutical Innovation. Available online: https:\/\/www.deloitte.com\/ch\/en\/Industries\/life-sciences-health-care\/research\/measuring-return-from-pharmaceutical-innovation.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pinzi, L., Bisi, N., and Rastelli, G. (2024). How drug repurposing can advance drug discovery: Challenges and opportunities. Front. Drug Discov., 4.","DOI":"10.3389\/fddsv.2024.1460100"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: A brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Udrescu, L., Sb\u00e2rcea, L., Top\u00eerceanu, A., Iovanovici, A., Kurunczi, L., Bogdan, P., and Udrescu, M. (2016). Clustering drug-drug interaction networks with energy model layouts: Community analysis and drug repurposing. Sci. Rep., 6.","DOI":"10.1038\/srep32745"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Siminea, N., Popescu, V., Sanchez Martin, J.A., Florea, D., Gavril, G., Gheorghe, A.M., I\u0163cu\u015f, C., Kanhaiya, K., Pacioglu, O., and Popa, L.I. (2022). Network analytics for drug repurposing in COVID-19. Briefings Bioinform., 23.","DOI":"10.1093\/bib\/bbab490"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1038\/s41591-024-03233-x","article-title":"A foundation model for clinician-centered drug repurposing","volume":"30","author":"Huang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2017.08.011","article-title":"Estrogen and progesterone signalling in the normal breast and its implications for cancer development","volume":"466","author":"Hilton","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Clusan, L., Ferri\u00e8re, F., Flouriot, G., and Pakdel, F. (2023). A basic review on estrogen receptor signaling pathways in breast cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076834"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, N., Grimshaw, A.A., Axson, S.A., Choe, S.H., and Miller, J.E. (2022). Drug repurposing: A systematic review on root causes, barriers and facilitators. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08272-z"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: Terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_29","unstructured":"WHO\/EURO (2025, August 28). Repurposing of Medicines in Oncology\u2014The Underrated Champion of Sustainable Innovation. Available online: https:\/\/www.who.int\/europe\/publications\/i\/item\/WHO-EURO-2021-2807-42565-59178."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lotfi Shahreza, M., Ghadiri, N., and Green, J.R. (2020). A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-65658-x"},{"key":"ref_31","unstructured":"Udrescu, L., and Sbarcea, L. (2020). The New Tale of Some Old Drugs. Proceedings of the 17th Romanian National Congress oh Pharmacy\u201421st Century Pharmacy\u2014Between Intelligent Specialization and Social Responsibility, Bucharest, Romania, 26\u201329 September 2018, Proceedings, Filodiritto."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"36181","DOI":"10.1039\/D1RA05320E","article-title":"Computational methods directed towards drug repurposing for COVID-19: Advantages and limitations","volume":"11","author":"Sharma","year":"2021","journal-title":"RSC Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: An effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorganic Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41467-025-56690-4","article-title":"Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"16","author":"Cummings","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Patil, R., Takate, H., Shanbhag, G., Sonawane, H.K., Padakanti, A.P., and Chella, N. (2024). Clinical Trials on Repurposed Drugs: An Overview. Drug Repurposing: Innovative Approaches to Drug Discovery and Development, Springer.","DOI":"10.1007\/978-981-97-5016-0_9"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Nowak, A.Z., and Romanowicz, H. (2022). Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature). Cancers, 14.","DOI":"10.3390\/cancers14102569"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, S., and Wang, X. (2021). The metabolic mechanisms of breast cancer metastasis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.602416"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 353, 2747\u20132757.","DOI":"10.1056\/NEJMoa052258"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rej, R.K., Roy, J., and Allu, S.R. (2024). Therapies for the treatment of advanced\/metastatic estrogen receptor-positive breast cancer: Current situation and future directions. Cancers, 16.","DOI":"10.3390\/cancers16030552"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor\u2013positive metastatic breast cancer: American Society of Clinical Oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: An overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/OP.22.00483","article-title":"Role of immunotherapy in breast cancer","volume":"19","author":"Jacob","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Badkas, A., De Landtsheer, S., and Sauter, T. (2021). Topological network measures for drug repositioning. Briefings Bioinform., 22.","DOI":"10.1093\/bib\/bbaa357"},{"key":"ref_48","first-page":"682","article-title":"Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era","volume":"18","author":"Cheng","year":"2017","journal-title":"Briefings Bioinform."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Udrescu, L., Bogdan, P., Chi\u015f, A., S\u00eerbu, I.O., Top\u00eerceanu, A., V\u0103ru\u0163, R.M., and Udrescu, M. (2020). Uncovering new drug properties in target-based drug\u2013drug similarity networks. Pharmaceutics, 12.","DOI":"10.1101\/2020.03.12.988600"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chen, H.R., Sherr, D.H., Hu, Z., and DeLisi, C. (2016). A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med. Genom., 9.","DOI":"10.1186\/s12920-016-0212-7"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Vitali, F., Cohen, L.D., Demartini, A., Amato, A., Eterno, V., Zambelli, A., and Bellazzi, R. (2016). A network-based data integration approach to support drug repurposing and multi-target therapies in triple negative breast cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162407"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/bioinformatics\/btab826","article-title":"A network-based drug repurposing method via non-negative matrix factorization","volume":"38","author":"Sadeghi","year":"2022","journal-title":"Bioinformatics"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jadamba, E., and Shin, M. (2016). A systematic framework for drug repositioning from integrated omics and drug phenotype profiles using pathway-drug network. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/7147039"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Meng, Y., Lu, C., Jin, M., Xu, J., Zeng, X., and Yang, J. (2022). A weighted bilinear neural collaborative filtering approach for drug repositioning. Briefings Bioinform., 23.","DOI":"10.1093\/bib\/bbab581"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Munj, S.A., Taz, T.A., Arslanturk, S., and Heath, E.I. (2022). Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1015531"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Firoozbakht, F., Rezaeian, I., Rueda, L., and Ngom, A. (2022). Computationally repurposing drugs for breast cancer subtypes using a network-based approach. BMC Bioinform., 23.","DOI":"10.1186\/s12859-022-04662-6"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/bioinformatics\/btab191","article-title":"Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug\u2013drug links based on graph neural network","volume":"37","author":"Cui","year":"2021","journal-title":"Bioinformatics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1747-0285.2011.01127.x","article-title":"Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies","volume":"78","author":"Thangapandian","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1039\/c2cs35357a","article-title":"Drug repositioning by structure-based virtual screening","volume":"42","author":"Ma","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: Challenges and recent advances","volume":"15","author":"Yang","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: Methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00109-019-01750-8","article-title":"FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells","volume":"97","author":"Hamurcu","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12032-024-02427-0","article-title":"A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells","volume":"41","author":"Abusharkh","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Majumder, S., Lodh, E., and Chowdhury, T. (2024). Implications of trinodal inhibitions and drug repurposing in MAPK pathway: A putative remedy for breast cancer. Comput. Biol. Chem., 113.","DOI":"10.1016\/j.compbiolchem.2024.108255"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: The DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Balbuena-Rebolledo, I., Padilla-Mart\u00ednez, I.I., Rosales-Hern\u00e1ndez, M.C., and Bello, M. (2021). Repurposing FDA drug compounds against breast cancer by targeting EGFR\/HER2. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080791"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bcp.2013.12.007","article-title":"Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling","volume":"87","author":"Koval","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2019.02.018","article-title":"Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor","volume":"449","author":"Ahmed","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"103730","DOI":"10.1016\/j.critrevonc.2022.103730","article-title":"Drug repositioning for cancer in the era of AI, big omics, and real-world data","volume":"175","author":"Wieder","year":"2022","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"giad011","DOI":"10.1093\/gigascience\/giad011","article-title":"The curse and blessing of abundance\u2014The evolution of drug interaction databases and their impact on drug network analysis","volume":"12","author":"Udrescu","year":"2023","journal-title":"GigaScience"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2411325","DOI":"10.1002\/advs.202411325","article-title":"Applications of Artificial Intelligence in Drug Repurposing","volume":"12","author":"Wan","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_72","unstructured":"(2025, April 14). Available online: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/artificial-intelligence-drug-development."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1093\/bioinformatics\/btaa577","article-title":"MDIPA: A microRNA\u2013drug interaction prediction approach based on non-negative matrix factorization","volume":"36","author":"Jamali","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","article-title":"Validating drug repurposing signals using electronic health records: A case study of metformin associated with reduced cancer mortality","volume":"22","author":"Xu","year":"2015","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12935-023-03176-2","article-title":"Artificial intelligence-driven new drug discovery targeting serine\/threonine kinase 33 for cancer treatment","volume":"23","author":"Tran","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yu, K., Basu, A., Yau, C., Wolf, D.M., Goodarzi, H., Bandyopadhyay, S., Korkola, J.E., Hirst, G.L., Asare, S., and DeMichele, A. (2023). Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1192208"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Khanjani, F., Jafari, L., Azadiyan, S., Roozbehi, S., Moradian, C., Zahiri, J., Hasannia, S., and Sajedi, R.H. (2021). Drug repositioning based on gene expression data for human HER2-positive breast cancer. Arch. Biochem. Biophys., 712.","DOI":"10.1016\/j.abb.2021.109043"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/bioinformatics\/bty325","article-title":"EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy","volume":"34","author":"Zhou","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Pedroza, R.A., Espinal-Enr\u00edquez, J., and Hern\u00e1ndez-Lemus, E. (2018). Pathway-based drug repositioning for breast cancer molecular subtypes. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00905"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Li, L., Hu, M., Wang, T., Chen, H., and Xu, L. (2020). Repositioning aspirin to treat lung and breast cancers and overcome acquired resistance to targeted therapy. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01503"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","article-title":"Cuproptosis: A copper-triggered modality of mitochondrial cell death","volume":"32","author":"Tang","year":"2022","journal-title":"Cell Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Xiao, C., Wang, X., Li, S., Zhang, Z., Li, J., Deng, Q., Chen, X., Yang, X., and Li, Z. (2025). A cuproptosis-based nanomedicine suppresses triple negative breast cancers by regulating tumor microenvironment and eliminating cancer stem cells. Biomaterials, 313.","DOI":"10.1016\/j.biomaterials.2024.122763"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1038\/s41467-024-54469-7","article-title":"Regulating copper homeostasis of tumor cells to promote cuproptosis for enhancing breast cancer immunotherapy","volume":"15","author":"Guan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Zhang, X., Shi, X., Zhang, X., Zhang, Y., Yu, S., Zhang, Y., and Liu, Y. (2024). Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. Biomed. Pharmacother., 178.","DOI":"10.1016\/j.biopha.2024.117293"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Al-Taie, Z., Hannink, M., Mitchem, J., Papageorgiou, C., and Shyu, C.R. (2021). Drug repositioning and subgroup discovery for precision medicine implementation in triple negative breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13246278"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"887-e416","DOI":"10.1634\/theoncologist.2019-0231","article-title":"A phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer","volume":"24","author":"Shafique","year":"2019","journal-title":"Oncologist"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease\u2013free survival in patients with breast cancer: The MA. 32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_89","unstructured":"(2025, July 27). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03323346."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: A population-based study","volume":"29","author":"Barron","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-021-06210-x","article-title":"Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer","volume":"188","author":"Hopson","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_92","first-page":"535","article-title":"Antihypertensive drug use and the risk of prostate cancer (Canada)","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes Control"},{"key":"ref_93","first-page":"680","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014Propranolol as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Foltz, S.M., Greene, C.S., and Taroni, J.N. (2023). Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04588-6"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.12793\/tcp.2021.29.e18","article-title":"The use of real-world data in drug repurposing","volume":"29","author":"Park","year":"2021","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"103422","DOI":"10.1016\/j.drudis.2022.103422","article-title":"Drug repurposing using real-world data","volume":"28","author":"Tan","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1007\/s10462-022-10306-1","article-title":"Deep learning in drug discovery: An integrative review and future challenges","volume":"56","author":"Askr","year":"2023","journal-title":"Artif. Intell. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/spe.3202","article-title":"Reproducibility as a service","volume":"53","author":"Wonsil","year":"2023","journal-title":"Software Pract. Exp."},{"key":"ref_99","first-page":"e70004","article-title":"What is reproducibility in artificial intelligence and machine learning research?","volume":"46","author":"Desai","year":"2025","journal-title":"AI Mag."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: Progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-019-0621-4","article-title":"Window of opportunity clinical trial designs to study cancer metabolism","volume":"122","author":"Aroldi","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","article-title":"Phase 0 and window of opportunity clinical trial design in neuro-oncology: A RANO review","volume":"22","author":"Vogelbaum","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10549-011-1612-1","article-title":"Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial","volume":"128","author":"Hadad","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2015.12.005","article-title":"Window of opportunity studies: Do they fulfil our expectations?","volume":"43","author":"Schmitz","year":"2016","journal-title":"Cancer Treat. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:09Z","timestamp":1760035389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":104,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091640"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091640","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}